Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Does secondary surgical cytoreduction improve survival in women with advanced ovarian cancer?

Nature Clinical Practice Oncology volume 2, pages 188–189 (2005)Cite this article

boxed-textRose PG et al. (2004) Secondary surgical cytoreduction for advanced ovarian carcinoma. N Engl J Med 351: 2489–2497

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. van der Burg ME et al. (1995) The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynaecologic Cooperative Group of the EORTC N Engl J Med 332: 629–634

    Article  CAS  Google Scholar 

  2. Schwartz PE et al. (1999) Neoadjuvant chemotherapy for advanced ovarian cancer: long-term survival. Gynecol Oncol 72: 93–99

    Article  CAS  Google Scholar 

  3. Vergote I et al. (1998) Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients. Gynecol Oncol 71: 431–436

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Alexandra King, Assistant Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Director of Gynecologic Oncology at Wayne State University, MI, USA

    Adnan Munkarah

Authors
  1. Adnan Munkarah
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The author declares no competing financial interests.

Glossary

PROGRESSION

An increase in serum cancer antigen 125 to ≥100 U/ml, or a clinically evident increase in disease

Rights and permissions

Reprints and permissions

About this article

Cite this article

Munkarah, A. Does secondary surgical cytoreduction improve survival in women with advanced ovarian cancer?. Nat Rev Clin Oncol 2, 188–189 (2005). https://doi.org/10.1038/ncponc0131

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncponc0131

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing